OBJECTIVE: To compare outcomes in patients with type 2 diabetes initiating insulin lispro mix 75/25 (75% insulin lispro protamine suspension and 25% lispro) or insulin glargine therapy, stratified by baseline oral antihyperglycemic agent (OHA) use. METHODS: We performed a post hoc analysis of 6-month data from the DURABLE clinical trial, which enrolled patients with hemoglobin A1c (A1C) levels >7.0% treated with 2 or moreOHAs (metformin, sulfonylurea, and thiazolidinedione), and randomly assigned them to treatment with twice-daily insulin lispro 75/25 or once-daily glargine. RESULTS: In both insulin treatment groups, metformin/thiazolidinedione-treated patients had significantly greater improvement in A1C levels (-2.19% to -2.36%), lower end point A1C values, and lower rates of occurrence of hypoglycemia in comparison with metformin/sulfonylurea-treated patients (all P<.05). Patients treated with sulfonylurea/thiazolidinedione or metformin/sulfonylurea/thiazolidinedione did not differ significantly from metformin/sulfonylurea-treated patients in A1C change (-1.56% to -1.84%) or rates of occurrence of hypoglycemia. CONCLUSION: In these post hoc analyses, patients with type 2 diabetes initiating premixed orbasal insulin therapy and treated concomitantly with the OHA combination of metformin/thiazolidinedione at baseline demonstrated significantly greater A1C improvement with less hypoglycemia in comparison with patients treated with metformin/sulfonylurea.
RCT Entities:
OBJECTIVE: To compare outcomes in patients with type 2 diabetes initiating insulin lispro mix 75/25 (75% insulin lispro protamine suspension and 25% lispro) or insulinglargine therapy, stratified by baseline oral antihyperglycemic agent (OHA) use. METHODS: We performed a post hoc analysis of 6-month data from the DURABLE clinical trial, which enrolled patients with hemoglobin A1c (A1C) levels >7.0% treated with 2 or more OHAs (metformin, sulfonylurea, and thiazolidinedione), and randomly assigned them to treatment with twice-daily insulin lispro 75/25 or once-daily glargine. RESULTS: In both insulin treatment groups, metformin/thiazolidinedione-treated patients had significantly greater improvement in A1C levels (-2.19% to -2.36%), lower end point A1C values, and lower rates of occurrence of hypoglycemia in comparison with metformin/sulfonylurea-treated patients (all P<.05). Patients treated with sulfonylurea/thiazolidinedione or metformin/sulfonylurea/thiazolidinedione did not differ significantly from metformin/sulfonylurea-treated patients in A1C change (-1.56% to -1.84%) or rates of occurrence of hypoglycemia. CONCLUSION: In these post hoc analyses, patients with type 2 diabetes initiating premixed or basal insulin therapy and treated concomitantly with the OHA combination of metformin/thiazolidinedione at baseline demonstrated significantly greater A1C improvement with less hypoglycemia in comparison with patients treated with metformin/sulfonylurea.
Authors: Monika Lechleitner; Michael Roden; Raimund Weitgasser; Bernhard Ludvik; Peter Fasching; Friedrich Hoppichler; Alexandra Kautzky-Willer; Guntram Schernthaner; Rudolf Prager; Thomas C Wascher Journal: Wien Klin Wochenschr Date: 2016-04 Impact factor: 1.704
Authors: Monika Lechleitner; Martin Clodi; Heidemarie Abrahamian; Helmut Brath; Johanna Brix; Heinz Drexel; Peter Fasching; Bernhard Föger; Claudia Francesconi; Elke Fröhlich-Reiterer; Jürgen Harreiter; Sabine E Hofer; Friedrich Hoppichler; Joakim Huber; Susanne Kaser; Alexandra Kautzky-Willer; Bernhard Ludvik; Anton Luger; Julia K Mader; Bernhard Paulweber; Thomas Pieber; Rudolf Prager; Birgit Rami-Merhar; Michael Resl; Michaela Riedl; Michael Roden; Christoph H Saely; Christian Schelkshorn; Guntram Schernthaner; Harald Sourij; Lars Stechemesser; Harald Stingl; Hermann Toplak; Thomas C Wascher; Raimund Weitgasser; Yvonne Winhofer-Stöckl; Sandra Zlamal-Fortunat Journal: Wien Klin Wochenschr Date: 2019-05 Impact factor: 1.704
Authors: Monika Lechleitner; Michael Roden; Raimund Weitgasser; Bernhard Ludvik; Peter Fasching; Friedrich Hoppichler; Alexandra Kautzky-Willer; Guntram Schernthaner; Rudolf Prager; Thomas C Wascher Journal: Wien Klin Wochenschr Date: 2012-12 Impact factor: 1.704